Alterity Therapeutics Secures $40M to Accelerate Next-Generation Treatments for Neurodegeneration

Alterity Therapeutics is thrilled to announce that we have successfully raised $40,000,000 in our latest funding round, a major milestone in our journey toward transforming the future for people living with neurodegenerative diseases. As a clinical stage biotechnology company with offices in Melbourne and San Francisco, we are committed to modifying the course of debilitating conditions like Parkinson’s disease and various Parkinsonian disorders, including Multiple System Atrophy (MSA). With our lead asset, ATH434, we are forging an alternate future for patients by targeting the underlying causes of neurodegeneration. ATH434 is an innovative oral agent designed to inhibit the aggregation of pathological proteins that contribute to disease progression. Preclinical studies have demonstrated its remarkable ability to reduce α-synuclein pathology and preserve nerve cells, primarily by restoring a healthy iron balance in the brain. This unique mechanism positions ATH434 as a promising therapeutic candidate, currently under evaluation in a global Phase 2 clinical trial in patients with early-stage MSA, generating significant anticipation within the clinical community. The new funding will not only accelerate the ongoing clinical development of ATH434 but also bolster our robust drug discovery platform, which is consistently generating patentable chemical compounds with the potential to intervene in complex disease processes. We plan to deepen our research efforts and expand our clinical programs, ensuring that our innovations reach patients as efficiently and safely as possible. This strategic investment reaffirms the confidence that our investors and partners have in our vision to redefine treatment landscapes for neurodegenerative diseases and improve the quality of life for those in need.